7月28日，百特国际盘中上涨5.01%，报24.53美元/股，成交额3582.54万美元。
消息面上，Stifel将百特国际目标价从19美元大幅上调至24美元，维持持有评级。值得注意的是，近期多家投行集中上调百特目标价：高盛7月14日将目标价从19美元上调至21美元，Evercore ISI 7月初将目标价从22美元上调至24美元。当前FactSet统计的分析师平均目标价为21美元。此外，公司将于7月30日盘前发布季度财报，市场预期每股收益为0.36美元，投行集中上调目标价或反映市场对公司基本面改善的预期升温。
百特国际提供广泛的基本医疗保健产品，包括无菌静脉溶液、输液系统和设备、肠外营养疗法、吸入麻醉剂、仿制注射剂及手术止血剂等。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.